<DOC>
	<DOCNO>NCT02035137</DOCNO>
	<brief_summary>This study compare three treatment regimen contain metaiodobenzylguanidine ( MIBG ) compare effect tumor response associate side effect , determine one therapy well people diagnose relapsed persistent neuroblastoma .</brief_summary>
	<brief_title>131I-MIBG Alone VS. 131I-MIBG With Vincristine Irinotecan VS131I-MIBG With Vorinistat</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Patients must &gt; 24 month &lt; 30 year age register study . Patients must relapse neuroblastoma , refractory neuroblastoma less partial response standard treatment persistent neuroblastoma least partial response frontline therapy frontline therapy &gt; 3 residual lesion endinduction MIBG scan . Patients must evidence MIBG uptake tumor â‰¥ one site within 4 week prior entry study subsequent intervening therapy . Patients must adequate heart , kidney , liver bone marrow function . Patients bone marrow disease must still adequate bone marrow function enter study . Patients must dose unpurged peripheral blood stem cell 2.0 x 106 viable CD34+ cells/kg available . They previous I131 MIBG therapy They medical problem could get much bad treatment . They pregnant breast feed . They history venous arterial thrombosis associate central line . They active infection hepatitis fungal infection . They active diarhhea . They allogeneic stem cell transplant ( received stem cell someone else ) They ca n't cooperate special precaution need trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>